CFDE Data Portal | Search B4GAT1-DT

	Label	Description
	B4GAT1-DT Gene (Entity type)	ENSG00000255468 - B4GAT1 divergent transcript
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS

B4GAT1-DT

ENSG00000255468 - B4GAT1 divergent transcript

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE189035 inositol 2 v 4 human dn

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.